quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:48:35·13d
SECFiling
TransMedics Group Inc. logo

SEC Form DEF 14A filed by TransMedics Group Inc.

TMDX· TransMedics Group Inc.
Health Care
Original source

Companies

  • TMDX
    TransMedics Group Inc.
    Health Care

Recent analyst ratings

  • Oct 23UpdateNeedham$148.00
  • Oct 13UpdateJefferies$145.00
  • Sep 16UpdateEvercore ISI$155.00
  • Sep 4UpdateStifel$115.00
  • Dec 17UpdateAnalyst$75.00
  • Nov 22UpdateNeedham-

Related

  • PR22h
    TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
  • PR2d
    TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
  • SEC13d
    SEC Form DEFA14A filed by TransMedics Group Inc.
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by TransMedics Group Inc.
  • INSIDER41d
    SEC Form 3 filed by new insider Forsyth Matthew S.
  • INSIDER48d
    Director Lovell Stephanie sold $178,497 worth of shares (1,193 units at $149.62), decreasing direct ownership by 29% to 2,866 units (SEC Form 4)
  • INSIDER48d
    Director Weill David exercised 3,571 shares at a strike of $14.20 and sold $524,294 worth of shares (3,571 units at $146.82) (SEC Form 4)
  • INSIDER50d
    Chief Financial Officer Hernandez Gerardo sold $1,117,382 worth of shares (7,611 units at $146.81) and exercised 7,236 shares at a strike of $71.17, decreasing direct ownership by 2% to 14,689 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022